SKB-105

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameSKB-105
Drug Alias NameSKB105SKB-105PR023PR-023CR-003 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > T01 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-ITGB6DNA topoisomerase I modulators
TargetsIntegrin beta-6DNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co LtdParagon Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCrescent Biopharma Operating Company LLCCrescent Biopharma IncSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A